Table 4.
Comparing the data and results from eight similar studies that have investigated invasive breast cancer within a population of young women
| Patient numbers | Average tumour size (mm) | Grade 3 tumours (%) | Lymph node involved (%) | Estrogen receptor negative (%) | HER2 receptor positive (%) | Overall survival at 5 years (%) | Overall survival at 10 years (%) | Median follow-up (months) | |
|---|---|---|---|---|---|---|---|---|---|
| McAree et al8 | 57 | 21.3 | 40.7 | 40.0 | 23.8 | 30.0 | 77.0 | – | 52.7 |
| Karihtala et al9 | 269 | – | 46.0 | 52.4 | 33.5 | 15.2 | 80.0 | 71.0 | 74.0 |
| Jayasinghe et al3 | 47 | – | 31.9 | 53.2 | – | – | 60.0 | 49.0 | – |
| Sidoni et al2 | 50 | 22.8 | 38.0 | 53.0 | 46.0 | 48.0 | – | – | – |
| Gillett et al21 | 58 | 23.0 | 40.0 | 34.0 | – | – | 90.0* | – | 31.0 |
| Sundquist et al7 | 107 | – | 64.0 | 37.0 | – | – | 72.0 | 58–63† | 134.0 |
| Fredholm et al5 | 1329 | – | 21.0‡ | 46.0 | 26.0‡ | – | 83.8 | – | – |
| Copson et al20 | 2956 | 22.0 | 58.9 | 50.6 | 33.7 | 24.3 | 81.9 | – | 60 |
| Current study | 92 | 20.1 | 55.4 | 42.5 | 20.7§ | 6.5 | 79.3 | 77.2 | 113.5 |
*Sixteen per cent of patients were pure ductal carcinoma in situ.
†Two figures recorded depending on study period.
‡Data missing for the tumour grade in 60% and estrogen receptor status in 18% of patients.
§Estrogen receptor positive if Allred score was greater than 3/8.